meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 1st line (L1)
1
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus lenalidomide and dexamethasone
versus all
vs Immunosuppressant
vs lenalidomide based treatment
vs lenalidomide and dexamethasone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded